[Question] non-peptide — what am I missing here
Trying to get a straight answer on this: non-peptide — what am I missing here. What is actually known, and what is being assumed. Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the…
Retitled to name the programme. It is what makes these threads findable in a year.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
Is that from the publication or the press release?
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.
a non-peptide agonist does not degrade the way a peptide does
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Are you comparing doses across a small molecule and a peptide?
nothing containing this is approved anywhere and research material is not for human use
Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.